Peripheral blood reverse transcription PCR assay for prostate stem cell antigen correlates with androgen-independent progression in advanced prostate cancer

2011 ◽  
Vol 131 (4) ◽  
pp. 902-910 ◽  
Author(s):  
Zhigang Zhao ◽  
Guohua Zeng ◽  
Wenjing Ma ◽  
Lili Ou ◽  
Yeping Liang
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Reverse Transcription ◽  
Peripheral Blood ◽  
Advanced Prostate Cancer ◽  
Prostate Stem Cell Antigen ◽  
Pcr Assay ◽  
Cell Antigen ◽  
Reverse Transcription Pcr ◽  
Androgen Independent

scholarly journals [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model

2019 ◽  
Vol 22 (2) ◽  
pp. 367-376 ◽  
Author(s):  
Kirstin A. Zettlitz ◽  
Wen-Ting K. Tsai ◽  
Scott M. Knowles ◽  
Felix B. Salazar ◽  
Naoko Kobayashi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Human Prostate ◽  
Prostate Stem Cell Antigen ◽  
Cell Antigen ◽  
Syngeneic Model

scholarly journals Quantitative Reverse Transcription-PCR Assay with an Internal Standard for the Detection of Prostate-specific Antigen mRNA

1999 ◽  
Vol 45 (9) ◽  
pp. 1397-1407 ◽  
Author(s):  
Alice Ylikoski ◽  
Minna Sjöroos ◽  
Åke Lundwall ◽  
Matti Karp ◽  
Timo Lövgren ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Detection Limit ◽  
Prostate Specific Antigen ◽  
Reverse Transcription ◽  
Specific Antigen ◽  
Internal Standard ◽  
Quantitative Detection ◽  
Rt Pcr ◽  
Pcr Assay ◽  
Reverse Transcription Pcr

Abstract Background: Circulating prostate cells can be detected with a reverse transcription-PCR (RT-PCR) assay for prostate-specific antigen (PSA) mRNA. We have developed a new quantitative RT-PCR method for measuring PSA mRNA. Methods: The method uses a PSA-like internal standard (IS) mRNA that is added into the sample at the beginning of the RNA extraction and coamplified by RT-PCR with the PSA in the sample. After PCR amplification, the IS and PSA products are selectively detected by hybridization in a microtitration plate using probes labeled with fluorescent europium chelates. Results: The method was validated with PSA and IS mRNAs and PSA-expressing cells to obtain a detection limit of 50 PSA mRNA copies (i.e., signal 2 times the mean of zero signal), linearity up to 106 copies, and detection of a single PSA-expressing cell. In preliminary evaluations, 60% (n = 10) of the prostate cancer patients with skeletal metastases gave results above the detection limit (500 PSA mRNA copies in 5 mL of blood). The total number of PSA copies ranged from 900 ± 200 to 44 100 ± 4900 (mean ± SD) in the samples, corresponding to ∼1–100 PSA-expressing cells in 5 mL of blood. In the controls (n = 34), none of the healthy females and 2 of 19 healthy males had detectable PSA mRNA [700 ± 100 and 2000 ± 900 (mean ± SD) PSA mRNA copies in 5 mL of blood for the 2 males]. Conclusions: The assay provides sensitive and quantitative detection of PSA mRNA expression from blood samples and can be used to establish the clinically significant number of PSA mRNA copies in prostate cancer.

Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter

The Prostate ◽  
2009 ◽  
Vol 69 (13) ◽  
pp. 1422-1434 ◽  
Author(s):  
Frank A. Petrigliano ◽  
Mandeep S. Virk ◽  
Nancy Liu ◽  
Osamu Sugiyama ◽  
Duan Yu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cell ◽  
Cancer Cells ◽  
Lentiviral Vector ◽  
Prostate Stem Cell Antigen ◽  
Prostate Cancer Cells ◽  
Cell Antigen
Sign in / Sign up

Export Citation Format

Share Document